AstraZeneca PLCAZNNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year operating income growth rate
Percentile
P28
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -16.89% |
| Q3 2025 | 2.14% |
| Q2 2025 | -4.52% |
| Q1 2025 | 80.45% |
| Q4 2024 | -3.32% |
| Q3 2024 | -23.31% |
| Q2 2024 | -11.85% |
| Q1 2024 | 152.43% |
| Q4 2023 | -36.85% |
| Q3 2023 | -20.44% |
| Q2 2023 | -3.65% |
| Q1 2023 | 133.00% |
| Q4 2022 | -12.13% |
| Q3 2022 | 130.98% |
| Q2 2022 | -38.61% |
| Q1 2022 | 400.68% |
| Q4 2021 | 82.56% |
| Q3 2021 | -248.54% |
| Q2 2021 | -40.53% |
| Q1 2021 | 27.44% |
| Q4 2020 | 26.99% |
| Q3 2020 | -8.80% |
| Q2 2020 | 5.25% |
| Q1 2020 | 111.44% |
| Q4 2019 | -23.78% |
| Q3 2019 | 53.55% |
| Q2 2019 | -55.06% |
| Q1 2019 | 1.86% |
| Q4 2018 | 26.56% |
| Q3 2018 | 11.53% |
| Q2 2018 | 9.63% |
| Q1 2018 | 1.46% |
| Q4 2017 | -40.30% |
| Q3 2017 | 24.22% |
| Q2 2017 | 0.87% |
| Q1 2017 | -63.80% |
| Q4 2016 | 146.40% |
| Q3 2016 | 239.27% |
| Q2 2016 | -70.81% |
| Q1 2016 | -4.60% |